Series Salem et al. [18] Carr et al. [36] Kooby et al. [37] Group TACE1 RE TACE2 RE TACE3 RE Number of patients 122 123 691 99 44 27 Period 2001-2010 2001-2010 1999-2000 2000-2005 1996- 2003- Viral etiology (%) 58 50 34 39 57a 37 a Cirrhosis (%) 92 86 66 80 nr nr Solitary tumors (%) 47 45 nr nr 57 44 > 5 nodules (%) nr nr 37 26 nr nr Portal vein thrombosis (%) 0 0 42 28 30 52 Bilobar disease (%) 34 36 51 43 30b 30 b Child A (%) 55 54 nr nr 50 48 BCLC tumor stage (%)             Early (A) 39 35 nr nr nr nr Intermediate (B) 20 28 nr nr nr nr Advanced (C) 9 10 ≥ 42 ≥ 28 ≥ 30 ≥ 52 Median overall survival (months) 17.4 20.5c 8.5 11.5 d 6.0 6.0 e TACE: transarterial chemoembolization. RE: radioembolization. 1 mitomycin C + doxorubicin + cisplatin mixed with lipiodiol and followed by calibrated particles; 2 Gelfoam or calibrated particles avoiding stasis followed by cisplatin without lipiodol. 3 doxorubicin + cisplatin + mitomycin-C followed by PVA particles. nr: not reported. a: HCV only; b: aprox (as per the text); c p=0.232; d p=0.014; e p=0.7

Table 1: Results from comparative series of HCC patients treated by TACE and radioembolization [18,36,37].